Skip to main content

Clinical Trials Using Osimertinib

Review the clinical trials studying osimertinib on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-22 of 22

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Status: Active
Location: 454 locations
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer that has EGFR and MET Gene Changes (An Expanded Lung-MAP Treatment Trial)
Status: Active
Location: 421 locations
Osimertinib with or without Bevacizumab as Initial Treatment for Patients with EGFR-Mutant Lung Cancer
Status: Active
Location: 558 locations
Testing Osimertinib as a Treatment for Lung Cancers with an EGFR Exon 20 Change
Status: Active
Location: 248 locations
Osimertinib Alone or with Chemotherapy for EGFR-Mutant Lung Cancers
Status: Active
Location: 16 locations
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Active
Location: 12 locations
First in Human Study of AZD9592 in Solid Tumors
Status: Active
Location: 10 locations
A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People with EGFR-Mutated Lung Cancer That Has Spread to the Brain, ICON-RT Trial
Status: Active
Location: 8 locations
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Status: Active
Location: 8 locations
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Status: Active
Location: 5 locations
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Status: Active
Location: 4 locations
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Active
Location: 4 locations
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Status: Active
Location: 3 locations
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Status: Active
Location: 3 locations
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Status: Active
Location: 2 locations
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
Status: Active
Location: 2 locations
Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer
Status: Active
Location: 2 locations
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Status: Active
Location: University of Kentucky/Markey Cancer Center, Lexington, Kentucky
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Status: Active
Location: See ClinicalTrials.gov
Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)
Status: Active
Location: 1109 locations